Almac Successfully Completes KTP with Queens University with Highest Accolade
News Jan 28, 2013
Almac has announced the successful completion of the Knowledge Transfer Partnership (KTP) with Queens University Belfast, to develop, improve and embed bioprocesses in order to facilitate the delivery of novel products for its biocatalysis business.
The project was awarded the highest grade of “Outstanding” by the KTP Grading Panel for it’s achievement in meeting KTP’s objectives.
The overall partnership aim was to allow technology transfer of fermentation and molecular / microbiology expertise from Queens University to Almac.
Almac met the specific partnership objectives by not only sharing a program of work with academics at Queens, but also attending training courses organized through University College London and embedding key learning back into the company.
The resulting success of this collaboration is that Almac can now deliver a fully integrated fermentation, optimization and bio-product service to its customers.
Since completion of the KTP, Almac have successfully scaled fermentation and bio-oxidation reactions to thousands of litres.
Dr Tom Moody, Head of Biocatalysis and Radiolabelling Services, is understandably delighted with the results of this partnership: “To receive the highest grade of Outstanding is a huge achievement for Almac, and testament to the commitment of the team involved. Not only have we further strengthened our long-standing relationship with Queens University, but we have also increased our service offering within the biocatalysis field to our clients, thus allowing us to compete in an area which was previously beyond our reach.”
This achievement follows from an extremely successful year for Almac’s biocatalysis service offering.
2012 saw the launch of its metabolite synthesis services, winning a Belfast Telegraph Award in Excellence in Technology, and announcing an industry-leading biocatalysis collaboration with DSM Pharmaceutical Products.
Batavia Biosciences Teams Up with International Consortium to Support Polio EradicationNews
Batavia Biosciences announces its partnership with an international consortium coordinated by PATH aiming to develop and manufacture safer novel oral poliovirus vaccines (nOPV).READ MORE
Researchers Develop Novel ‘One-pot’ Approach to Conjugated Tetraenes SynthesisNews
TUAT researchers have achieved the new synthetic route of conjugated tetraenes from inexpensive and easily available 1,3-butadiene and substituted acetylenes by a one-pot approach under mild conditions. Conjugated tetraenes are important key substructures in biologically active natural products such as vitamins, and anti-mycotic drugs.READ MORE
Safety and Efficacy of MERS Treatment Confirmed in Phase I TrialNews
An experimental treatment developed from cattle plasma for Middle East respiratory syndrome (MERS) coronavirus infection shows broad potential, according to a small clinical trial. The treatment, SAB-301, was safe and well tolerated by healthy volunteers, with only minor reactions documented.READ MORE